via uk.reuters.com
Ratiopharm's remaining suitors, which also include Israel's Teva (TEVA.TA) and smaller Icelandic peer Actavis, had been requested to make final bids on Thursday at the latest, several sources had previously said.
Officials at Pfizer were not immediately available for comment.
So far, Actavis's offer has been the highest at about 3 billion euros ($4.10 billion), including assumed debt, sources have said.
No comments:
Post a Comment